GNRH1 and metastatic prostate carcinoma: Because it is androgen dependent, androgen deprivation therapy (ADT) is the mainstay systemic treatment in patients with metastatic carcinoma of the prostate.[5] It has also been widely used amongst those with less advanced disease.[6,7] To date, androgen deprivation can be achieved in several ways: surgically by performing bilateral orchiectomy, or pharmacologically with gonadotrophin-releasing hormone (GnRH) agonists such as luteinizing hormone-releasing hormone agonists (LHRHa), GnRH antagonists, and non-steroidal anti-androgen drugs such as bicalutamide and flutamide.